57.1 percent of physicians received payments; median payment was $48, but considerable variation seen in payments
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid
Timely anticipatory planning in early dementia is crucial to preserve autonomy over future decisions and to reduce caregiver strain